[Form 4] Mesa Laboratories Inc Insider Trading Activity
Mark Christopher Capone, a director of Mesa Laboratories, reported transactions on Form 4 showing equity from restricted stock units. On 08/15/2025 1,404 RSUs vested and were converted into 1,404 shares of common stock at a $0 price, increasing his reported beneficial ownership of common stock to 2,128 shares. The filing also reports an additional 2,784 RSUs that remain outstanding and vest on 08/15/2026. The Form 4 was executed under power of attorney by John Sakys and dated 08/18/2025. All transactions are routine equity compensation events; no cash purchase price was reported.
Mark Christopher Capone, amministratore di Mesa Laboratories, ha dichiarato operazioni su un Modulo 4 relative a equity derivanti da unit脿 di azioni vincolate (RSU). In data 15/08/2025 sono maturate 1.404 RSU, convertite in 1.404 azioni ordinarie a prezzo di $0, portando la sua partecipazione segnalata a 2.128 azioni ordinarie. Il deposito indica inoltre che restano in essere 2.784 RSU, che matureranno il 15/08/2026. Il Modulo 4 猫 stato firmato per procura da John Sakys in data 18/08/2025. Si tratta di operazioni ordinarie di retribuzione azionaria; non 猫 stato indicato alcun prezzo di acquisto in contanti.
Mark Christopher Capone, miembro del consejo de Mesa Laboratories, inform贸 operaciones en el Formulario 4 sobre acciones procedentes de unidades restringidas (RSU). El 15/08/2025 vencieron 1.404 RSU y se convirtieron en 1.404 acciones ordinarias a precio de $0, elevando su participaci贸n reportada a 2.128 acciones ordinarias. La presentaci贸n tambi茅n indica que permanecen pendientes 2.784 RSU que vencer谩n el 15/08/2026. El Formulario 4 fue firmado por poder por John Sakys y fechado el 18/08/2025. Todas las transacciones son eventos habituales de compensaci贸n en acciones; no se report贸 ning煤n precio de compra en efectivo.
Mark Christopher Capone電� Mesa Laboratories鞚� 鞚挫偓搿滌劀 鞝滍暅欤检嫕雼渼(RSU) 甏�霠� 雮挫棴鞚� Form 4鞐� 氤搓碃頄堨姷雼堧嫟. 2025-08-15鞐� 1,404 RSU臧� 靹标臣霅橃柎 霃欖澕頃� 靾橃潣 1,404 氤错喌欤茧 鞝勴櫂霅橃棃瓿�, 鞚措姅 $0鞚� 臧�瓴╈溂搿� 觳橂Μ霅橃柎 攴胳潣 氤错喌欤�(靻岇湢氤搓碃鞎�)毳� 2,128欤茧 電橂牳鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 於旉皜搿� 鞎勳 氙胳旮� 靸來儨鞚� 2,784 RSU臧� 雮晞 鞛堨溂氅� 鞚措摛鞚� 2026-08-15鞐� 靹标臣霅� 鞓堨爼鞚措澕瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. Form 4電� John Sakys臧� 鞙勳瀯鞛レ溂搿� 鞁ろ枆頄堨溂氅� 靹滊鞚检瀽電� 2025-08-18鞛呺媹雼�. 氇摖 瓯半灅電� 韱奠儊鞝侅澑 欤检嫕 氤挫儊 頄夓偓搿� 順勱笀 毵れ垬 雽�旮堨潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
Mark Christopher Capone, administrateur de Mesa Laboratories, a d茅clar茅 des op茅rations sur le formulaire 4 concernant des unit茅s d'actions restreintes (RSU). Le 15/08/2025, 1 404 RSU ont acquis droit et ont 茅t茅 converties en 1 404 actions ordinaires au prix de 0 $, portant sa participation d茅clar茅e 脿 2 128 actions ordinaires. Le d茅p么t indique 茅galement que 2 784 RSU restent en circulation et seront acquises le 15/08/2026. Le formulaire 4 a 茅t茅 sign茅 par procuration par John Sakys et dat茅 du 18/08/2025. Toutes les transactions rel猫vent d'茅v茅nements courants de r茅mun茅ration en actions ; aucun prix d'achat en esp猫ces n'a 茅t茅 indiqu茅.
Mark Christopher Capone, Direktor von Mesa Laboratories, meldete Transaktionen in Formular 4 im Zusammenhang mit Restricted Stock Units (RSU). Am 15.08.2025 sind 1.404 RSU f盲llig geworden und zu 1.404 Stammaktien zu einem Preis von $0 umgewandelt worden, wodurch sein gemeldeter wirtschaftlicher Aktienbesitz auf 2.128 Stammaktien anstieg. Die Einreichung weist au脽erdem darauf hin, dass noch 2.784 RSU ausstehen, die am 15.08.2026 f盲llig werden. Das Formular 4 wurde am 18.08.2025 von John Sakys per Vollmacht unterzeichnet. Alle Transaktionen sind routinem盲脽ige aktienbasierte Verg眉tungsereignisse; ein Bar-Kaufpreis wurde nicht angegeben.
- Timely disclosure of RSU vesting and outstanding awards under Section 16
- No cash outlay reported for vested RSUs, indicating standard compensation conversion
- None.
Insights
TL;DR: Routine director RSU vesting converted to 1,404 shares, modestly increasing insider ownership; no cash paid.
The filing documents a standard equity-compensation event with 1,404 RSUs vesting into shares and an outstanding balance of 2,784 RSUs vesting next year. This increases reported beneficial ownership to 2,128 shares. There is no sale or purchase for cash, and no change to outstanding option/convertible positions beyond the RSU movements. For investors, this is a disclosure of insider compensation rather than an operational or financial development.
TL;DR: Disclosure reflects compliance with Section 16 reporting for director compensation; timing and amounts are standard.
The Form 4 shows timely reporting of RSU vesting by a director and lists remaining RSUs that vest on 08/15/2026. The use of a power of attorney to sign the filing is common for administrative filings. There are no indications of unusual trading, pledging, or derivative exercises that would raise governance concerns in this submission.
Mark Christopher Capone, amministratore di Mesa Laboratories, ha dichiarato operazioni su un Modulo 4 relative a equity derivanti da unit脿 di azioni vincolate (RSU). In data 15/08/2025 sono maturate 1.404 RSU, convertite in 1.404 azioni ordinarie a prezzo di $0, portando la sua partecipazione segnalata a 2.128 azioni ordinarie. Il deposito indica inoltre che restano in essere 2.784 RSU, che matureranno il 15/08/2026. Il Modulo 4 猫 stato firmato per procura da John Sakys in data 18/08/2025. Si tratta di operazioni ordinarie di retribuzione azionaria; non 猫 stato indicato alcun prezzo di acquisto in contanti.
Mark Christopher Capone, miembro del consejo de Mesa Laboratories, inform贸 operaciones en el Formulario 4 sobre acciones procedentes de unidades restringidas (RSU). El 15/08/2025 vencieron 1.404 RSU y se convirtieron en 1.404 acciones ordinarias a precio de $0, elevando su participaci贸n reportada a 2.128 acciones ordinarias. La presentaci贸n tambi茅n indica que permanecen pendientes 2.784 RSU que vencer谩n el 15/08/2026. El Formulario 4 fue firmado por poder por John Sakys y fechado el 18/08/2025. Todas las transacciones son eventos habituales de compensaci贸n en acciones; no se report贸 ning煤n precio de compra en efectivo.
Mark Christopher Capone電� Mesa Laboratories鞚� 鞚挫偓搿滌劀 鞝滍暅欤检嫕雼渼(RSU) 甏�霠� 雮挫棴鞚� Form 4鞐� 氤搓碃頄堨姷雼堧嫟. 2025-08-15鞐� 1,404 RSU臧� 靹标臣霅橃柎 霃欖澕頃� 靾橃潣 1,404 氤错喌欤茧 鞝勴櫂霅橃棃瓿�, 鞚措姅 $0鞚� 臧�瓴╈溂搿� 觳橂Μ霅橃柎 攴胳潣 氤错喌欤�(靻岇湢氤搓碃鞎�)毳� 2,128欤茧 電橂牳鞀惦媹雼�. 鞝滌稖靹滊鞐愲姅 於旉皜搿� 鞎勳 氙胳旮� 靸來儨鞚� 2,784 RSU臧� 雮晞 鞛堨溂氅� 鞚措摛鞚� 2026-08-15鞐� 靹标臣霅� 鞓堨爼鞚措澕瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. Form 4電� John Sakys臧� 鞙勳瀯鞛レ溂搿� 鞁ろ枆頄堨溂氅� 靹滊鞚检瀽電� 2025-08-18鞛呺媹雼�. 氇摖 瓯半灅電� 韱奠儊鞝侅澑 欤检嫕 氤挫儊 頄夓偓搿� 順勱笀 毵れ垬 雽�旮堨潃 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.
Mark Christopher Capone, administrateur de Mesa Laboratories, a d茅clar茅 des op茅rations sur le formulaire 4 concernant des unit茅s d'actions restreintes (RSU). Le 15/08/2025, 1 404 RSU ont acquis droit et ont 茅t茅 converties en 1 404 actions ordinaires au prix de 0 $, portant sa participation d茅clar茅e 脿 2 128 actions ordinaires. Le d茅p么t indique 茅galement que 2 784 RSU restent en circulation et seront acquises le 15/08/2026. Le formulaire 4 a 茅t茅 sign茅 par procuration par John Sakys et dat茅 du 18/08/2025. Toutes les transactions rel猫vent d'茅v茅nements courants de r茅mun茅ration en actions ; aucun prix d'achat en esp猫ces n'a 茅t茅 indiqu茅.
Mark Christopher Capone, Direktor von Mesa Laboratories, meldete Transaktionen in Formular 4 im Zusammenhang mit Restricted Stock Units (RSU). Am 15.08.2025 sind 1.404 RSU f盲llig geworden und zu 1.404 Stammaktien zu einem Preis von $0 umgewandelt worden, wodurch sein gemeldeter wirtschaftlicher Aktienbesitz auf 2.128 Stammaktien anstieg. Die Einreichung weist au脽erdem darauf hin, dass noch 2.784 RSU ausstehen, die am 15.08.2026 f盲llig werden. Das Formular 4 wurde am 18.08.2025 von John Sakys per Vollmacht unterzeichnet. Alle Transaktionen sind routinem盲脽ige aktienbasierte Verg眉tungsereignisse; ein Bar-Kaufpreis wurde nicht angegeben.
FAQ
What did Mark Capone report on the Form 4 for MLAB?
When did the RSUs vest and when was the Form 4 filed?
Did Mark Capone pay anything to receive the vested shares?
How many RSUs remain outstanding for Mark Capone and when do they vest?
Does the Form 4 show any sale or derivative exercises by the reporting person?
